Trial · NCT04896008
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Confirmed Morbidity or Mortality Event | Sotatercept | NA | 95% Confidence Interval 25.4 to NA | Months | |
| Time to First Confirmed Morbidity or Mortality Event | Placebo | 9.6 | 95% Confidence Interval 5.9 to 14.8 | Months | |
| Overall Survival (OS) | Sotatercept | NA | 95% Confidence Interval 25.4 to NA | Months | |
| Overall Survival (OS) | Placebo | NA | 95% Confidence Interval NA to NA | Months | |
| Transplant-free Survival | Sotatercept | NA | 95% Confidence Interval 25.4 to NA | Months | |
| Transplant-free Survival | Placebo | NA | 95% Confidence Interval NA to NA | Months | |
| Percentage of Participants Who Experienced a Mortality Event | Sotatercept | 12.8 | Percentage of Participants | ||
| Percentage of Participants Who Experienced a Mortality Event | Placebo | 16.3 | Percentage of Participants | ||
| Change From Baseline in REVEAL Lite 2.0 Risk Score at Week 24 | Sotatercept | -3.0 | Full Range -9.0 to 2.0 | Scores on a scale | |
| Change From Baseline in REVEAL Lite 2.0 Risk Score at Week 24 | Placebo | -1.0 | Full Range -6.0 to 5.0 | Scores on a scale | |
| Percentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 24 | Sotatercept | 48.7 | Percentage of Participants | ||
| Percentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 24 | Placebo | 14.3 | Percentage of Participants | ||
| Change From Baseline in NT-proBNP Levels at Week 24 | Sotatercept | -1336.0 | Full Range -21790 to 961 | pg/mL | |
| Change From Baseline in NT-proBNP Levels at Week 24 | Placebo | 26.0 | Full Range -9782 to 16706 | pg/mL | |
| Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24 | Sotatercept | -15.0 | Full Range -50 to 7 | mmHg | |
| Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24 | Placebo | -1.0 | Full Range -56 to 25 | mmHg | |
| Change From Baseline in Pulmonary Vascular Resistance (PVR) | Sotatercept | -180.0 | Full Range -1504 to 720 | Dynes*sec/cm^5 | |
| Change From Baseline in Pulmonary Vascular Resistance (PVR) | Placebo | -40.0 | Full Range -872 to 920 | Dynes*sec/cm^5 | |
| Percentage of Participants Who Improve in WHO FC | Sotatercept | 54.7 | Percentage of Participants | ||
| Percentage of Participants Who Improve in WHO FC | Placebo | 30.2 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04896008/results